Skip to main content
. 2022 Sep 13;10(10):e1423–e1442. doi: 10.1016/S2214-109X(22)00330-8

Figure 2.

Figure 2

Maps of reported availability of inhaled medicines in LMICs

(A) Short-acting beta-agonist inhalers. (B) Inhaled corticosteroid inhalers. (C) Inhaled corticosteroid–long-acting beta-agonist combination inhalers. Availability means presence of inhaled medicines in 80% or more of studied facilities. LMICs=low-income and middle-income countries.